Ethanol Extract of Crataegus Oxyacantha L. Ameliorate Dietary Non-Alcoholic Fatty Liver Disease in Rat

Abstract

Background Non-alcoholic fatty liver (NAFLD) is one the most prevalent disease worldwide which characterized by fat accumulation in liver with no established efficient therapy. We designed this study to investigate protective and therapeutic effect of Crataegus oxyacantha L. (C. oxyacantha) on NAFLD induced by high fat diet in rat models.

Methods NAFLD was induced by High Fat Diet+fructose (HFD), 45 Wistar rats were divided to 8 groups including control, HFD, HFD+diet change, HFD+diet change+C. oxyacantha 20 mg/kg, co treatment of HFD+C. oxyacantha 10, 20 and 40 mg/kg, and normal diet+C. oxyacantha 40 mg. C. oxyacantha was administered orally. Effectiveness of the C. oxyacantha was assessed through measuring the biochemical factors, and oxidative stress marker (FRAP, GSH, and MDA). Histopathological study was performed using H & E staining.

Results The diet change from high fat to low fat ameliorated liver damage. However, consumption of C. oxyacantha (10 & 20 mg/kg) caused significant reduction in the level of all examined liver biomarkers specially LDH, that showed C. oxyacantha can restore the hepatocyte damage due to HFD. The C. oxyacantha showed a protective effect which was more prominent in the animals treated with the 20 mg/kg C. oxyacantha. The administration of C. oxyacantha caused increased antioxidant status (GSH and FRAP levels) and decreased lipid peroxidation in treated animals.

Major Conclusion Accordingly, C. oxyacantha have both therapeutic and protective effect for NAFLD and may be a potential candidate for further assessments in clinical studies.

Key words

non-alcoholic fatty liver disease - Crataegus oxyacantha L. - liver enzymes - Lipid peroxidation - Antioxidant status - High Fat Diet - fructose

• References

• 1 Yao H, Qiao YJ, Zhao YL. et al. Herbal medicines and nonalcoholic fatty liver disease. World J Gastroenterol. 2016; 22: 6890-6905
• 2 Benlhabib E, Baker JI, Keyler DE. et al. Effects of purified puerarin on voluntary alcohol intake and alcohol withdrawal symptoms in p rats receiving free access to water and alcohol. Journal of Medicinal Food 2004; 7: 180-186
• 3 Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: Pathology and pathogenesis. Annu Rev Pathol 2010; 5: 145-171
• 4 Lee JS, Jun DW, Kim EK. et al. Histologic and metabolic derangement in high-fat, high-fructose, and combination diet animal models. The Scientific World Journal 2015; 2015: 1-9
• 5 Takahashi Y, Sugimoto K, Inui H. et al. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21: 3777-3785
• 6 Del Ben M, Polimeni L, Baratta F. et al. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. Br J Clin Pharmacol 2017; 83: 88-95
• 7 Oridupa OA, Ovwighose NO, Saba AB. Anti-hyperglycaemic effect of cleome rutidosperma in alloxan-induced diabetic albino rats. Drug research 2017; 67: 719-723
• 8 Seeff LB, Bonkovsky HL, Navarro VJ. et al. Herbal products and the liver: A review of adverse effects and mechanisms. Gastroenterology. 2015; 148: 517-32.e3
• 9 Elahi A, Fereidooni A, Shahabinezhad F. et al. An overview of amenorrhea and respective remedies in Traditional Persian Medicine. Trends in Pharmaceutical Sciences 2016; 2: 3-10
• 10 Raza MA, Mukhtar F, Danish M. Cuscuta reflexa and Carthamus Oxyacantha: Potent sources of alternative and complimentary drug.. SpringerPlus 2015; 4: 1
• 11 Wang J, Xiong X, Feng B. Effect of crataegus usage in cardiovascular disease prevention: An evidence-based approach. Evid Based Complement Alternat Med 2013; 2013: 149363
• 12 Tassell M, Kingston R, Gilroy D. et al. Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease. Pharmacogn Rev 2010; 4: 32-41 doi: 104103/0973-784765324 2010; 4(7): 32-41
• 13 Orhan IE. Phytochemical and pharmacological activity profile of Crataegus oxyacantha L. (hawthorn) – A cardiotonic herb. Curr Med Chem. 2016 Sep 18. [Epub ahead of print]
• 14 Rahman K, Desai C, Iyer SS. et al. Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. Gastroenterology. 2016; 151: 733-746 e12
• 15 Shakibaie M, Shahverdi AR, Faramarzi MA. et al. Acute and subacute toxicity of novel biogenic selenium nanoparticles in mice. Pharmaceutical Biology 2013; 51: 58-63
• 16 Ergin M, Caliskanturk M, Senat A. et al. Disulfide stress in carbon monoxide poisoning. Clinical Biochemistry 2016; 49: 1243-1247
• 17 Gupta A, Kant S, Gupta SK. et al. Serum FRAP levels and pre-eclampsia among pregnant women in a rural community of Northern India. Journal of Clinical and Diagnostic Research: JCDR 2016; 10: LC12
• 18 Keshavarz-Bahaghighat H, Sepand MR, Ghahremani MH. et al. Acetyl-l-carnitine attenuates arsenic-induced oxidative stress and hippocampal mitochondrial dysfunction. Biological Trace Element Research 2017; 1-14
• 19 Green H, Tobar A, Gafter-Gvili A. et al. Serum Lactate Dehydrogenase is Elevated in Ischemic Acute Tubular Necrosis but Not in Acute Rejection in Kidney Transplant Patients. Prog Transplant 2017; 27: 53-57
• 20 Aggarwal BD. Lactate dehydrogenase as a biomarker for silica exposure-induced toxicity in agate workers. Occupational and Environmental Medicine 2014 oemed-2014-102190
• 21 Jin R, Welsh JA, Le N-A. et al. Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients 2014; 6: 3187-3201
• 22 Davoodi I, Rahimi R, Abdollahi M. et al. Promising effect of Rosa damascena extract on high-fat diet-induced nonalcoholic fatty liver. Journal of Traditional and Complementary Medicine 2017; 7: 508-514
• 23 Al Makdessi S, Sweidan H, Mullner S. et al. Myocardial protection by pretreatment with Crataegus oxyacantha: An assessment by means of the release of lactate dehydrogenase by the ischemic and reperfused Langendorff heart. Arzneimittel-Forschung 1996; 46: 25-27
• 24 Akila M, Devaraj H. Synergistic effect of tincture of Crataegus and Mangifera indica L. extract on hyperlipidemic and antioxidant status in atherogenic rats. Vasc Pharmacol 2008; 49: 173-177
• 25 Al Humayed S. Protective and therapeutic effects of Crataegus aronia in non-alcoholic fatty liver disease. Archives of Physiology and Biochemistry 2016; 1-8
• 26 Chang CL, Chen HS, Shen YC. et al. Phytochemical composition, antioxidant activity and neuroprotective effect of Crataegus pinnatifida fruit. South African Journal of Botany 2013; 88: 432-437
• 27 Edwards JE, Brown PN, Talent N. et al. A review of the chemistry of the genus Crataegus. Phytochemistry 2012; 79: 5-26
• 28 Keskin N, Mammadov R, Ili P. The effects of Crataegus aronia var. dentata Browicz extract on biochemical indices and apoptosis in partially hepatectomized liver in rats. Bosnian Journal of Basic Medical Sciences 2012; 12: 177
• 29 Ozay C, Mammadov R, Tasdelen G. et al. Potential antioxidant, antiproliferative and hepatoprotective effects of crataegus meyeri. Journal of Food Biochemistry 2015; 39: 548-553
• 30 Martinez-Rodriguez JL, Reyes-Estrada CA, Gutierrez-Hernandez R. et al. Antioxidant, hypolipidemic and preventive effect of Hawthorn (Crataegus oxyacantha) on alcoholic liver damage in rats. Journal of Pharmacognosy and Phytotherapy 2016; 8: 193-202
• 31 Shanthi S, Parasakthy K, Deepalakshmi PD. et al. Hypolipidemic activity of tincture of Crataegus in rats. Indian J Biochem Biophys. 1994; 31: 143-146
• 32 Akila M, Devaraj H. Synergistic effect of tincture of Crataegus and Mangifera indica L. extract on hyperlipidemic and antioxidant status in atherogenic rats. Vascul Pharmacol 2008; 49: 173-177
• 33 Li Z, Xu J, Zheng P. et al. Hawthorn leaf flavonoids alleviate nonalcoholic fatty liver disease by enhancing the adiponectin/AMPK pathway. Int J. Clin Exp Med 2015; 8: 17295-17307